Lyme borreliosis: Reviewing potential vaccines, clinical aspects and health economicsSmit, R. & Postma, M. J., 2-Dec-2015, In : Expert review of vaccines. 14, 12, p. 1549-1561 13 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Lyme borreliosis (LB) is a multisystem infectious disease with a growing burden in many parts of North America, Asia and Europe. Persistent infection of LB can usually be treated effectively with antibiotic therapy, but it may be followed by post-treatment Lyme disease syndrome. Therefore, it is important to begin with treatment in the early phase of the disease. Vaccination shows potential as the most effective way of preventing LB and reducing its burden in these continents. It is concluded that there is a need for continuous effort in research from all perspectives on LB, especially regarding prevention with novel vaccines, their development, clinical efficacy and cost-effectiveness. This review may help to further develop (cost-) effective strategies for prevention and control of the disease to reduce its burden and achieve population-wide health benefits.
|Number of pages||13|
|Journal||Expert review of vaccines|
|Publication status||Published - 2-Dec-2015|
- Borrelia burgdorferi, cost-effectiveness, health economics, Lyme borreliosis, Lyme disease, treatment, vaccines, BURGDORFERI-SENSU-LATO, SURFACE PROTEIN-A, TICK-BORNE ENCEPHALITIS, HUMAN GRANULOCYTIC EHRLICHIOSIS, MULTIVALENT OSPA VACCINE, IXODES-RICINUS TICKS, DISEASE VACCINE, COST-EFFECTIVENESS, ERYTHEMA MIGRANS, ANTIBIOTIC-TREATMENT